>
Switch to:

Akero Therapeutics Debt-to-EBITDA

: -0.02 As of Sep. 2020
View and export this data going back to 2019. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Akero Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $0.30 Mil. Akero Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2020 was $1.56 Mil. Akero Therapeutics's annualized EBITDA for the quarter that ended in Sep. 2020 was $-86.15 Mil. Akero Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2020 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

NAS:AKRO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.03   Med: 0   Max: 0
Current: -0.03
-0.03
0
NAS:AKRO's Debt-to-EBITDA is ranked lower than
99.99% of the 232 Companies
in the Biotechnology industry.

( Industry Median: 1.22 vs. NAS:AKRO: -0.03 )

Akero Therapeutics Debt-to-EBITDA Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Akero Therapeutics Annual Data
Dec17 Dec18 Dec19
Debt-to-EBITDA N/A 0.00 0.00

Akero Therapeutics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.01 0.00 -0.02
Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.

Akero Therapeutics Debt-to-EBITDA Distribution

* The bar in red indicates where Akero Therapeutics's Debt-to-EBITDA falls into.


Akero Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Akero Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2019 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -45.651
=0.00

Akero Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2020 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.303 + 1.564) / -86.152
=-0.02

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2020) EBITDA data.

Akero Therapeutics  (NAS:AKRO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Akero Therapeutics Debt-to-EBITDA Related Terms

Akero Therapeutics Debt-to-EBITDA Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)